MX2020002649A - Metodos para hacer y usar endoxifeno. - Google Patents
Metodos para hacer y usar endoxifeno.Info
- Publication number
- MX2020002649A MX2020002649A MX2020002649A MX2020002649A MX2020002649A MX 2020002649 A MX2020002649 A MX 2020002649A MX 2020002649 A MX2020002649 A MX 2020002649A MX 2020002649 A MX2020002649 A MX 2020002649A MX 2020002649 A MX2020002649 A MX 2020002649A
- Authority
- MX
- Mexico
- Prior art keywords
- endoxifen
- methods
- making
- present disclosure
- hormones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catalysts (AREA)
- Dental Preparations (AREA)
- Primary Cells (AREA)
- Paper (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556799P | 2017-09-11 | 2017-09-11 | |
| US201762556884P | 2017-09-11 | 2017-09-11 | |
| US201862624787P | 2018-01-31 | 2018-01-31 | |
| US201862693885P | 2018-07-03 | 2018-07-03 | |
| PCT/US2018/050272 WO2019051416A1 (en) | 2017-09-11 | 2018-09-10 | METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002649A true MX2020002649A (es) | 2020-09-25 |
Family
ID=65635248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002649A MX2020002649A (es) | 2017-09-11 | 2018-09-10 | Metodos para hacer y usar endoxifeno. |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11261151B2 (enExample) |
| EP (1) | EP3681491A4 (enExample) |
| JP (3) | JP7766316B2 (enExample) |
| KR (2) | KR20200052349A (enExample) |
| CN (2) | CN111328280A (enExample) |
| AU (3) | AU2018329202B2 (enExample) |
| CA (1) | CA3073836A1 (enExample) |
| IL (3) | IL272924B2 (enExample) |
| MX (1) | MX2020002649A (enExample) |
| SG (1) | SG11202002105WA (enExample) |
| TW (2) | TWI793165B (enExample) |
| WO (1) | WO2019051416A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
| JP7662204B2 (ja) * | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| CN110564962B (zh) * | 2019-10-14 | 2020-12-22 | 中南大学 | 一种黑白钨混合矿的冶炼方法 |
| CN113975279A (zh) * | 2021-10-13 | 2022-01-28 | 复旦大学附属肿瘤医院 | 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用 |
| MX2024008643A (es) * | 2022-01-12 | 2024-09-25 | Atossa Therapeutics Inc | Composiciones de (z)-endoxifeno y métodos de enriquecimiento de este. |
| IL316562A (en) * | 2022-04-26 | 2024-12-01 | Atossa Therapeutics Inc | High-dose and convenient formulations of endoxifen |
| TW202510843A (zh) * | 2023-07-19 | 2025-03-16 | 美商阿托薩醫療公司 | 因多昔芬（ｅｎｄｏｘｉｆｅｎ）組合物及其使用方法及其合成 |
| WO2025137145A1 (en) | 2023-12-18 | 2025-06-26 | Atossa Therapeutics, Inc. | Oral formulations of (z)-endoxifen and methods of use thereof |
| WO2025151443A1 (en) | 2024-01-08 | 2025-07-17 | Atossa Therapeutics, Inc. | Endoxifen for treatment of rare cancers |
| WO2025207636A1 (en) | 2024-03-25 | 2025-10-02 | Atossa Therapeutics, Inc. | Endoxifen for treating duchenne muscular dystrophy |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
| GB2160202B (en) | 1984-06-12 | 1987-12-02 | Nat Res Dev | Preparation of tamoxifen |
| GB8604528D0 (en) | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
| US6881548B2 (en) | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US6398765B1 (en) | 1999-03-01 | 2002-06-04 | Pro Duct Health, Inc. | Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts |
| US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
| WO2001001962A1 (en) | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
| US6416981B1 (en) | 2000-05-23 | 2002-07-09 | Nec Partnership | Production of gluconate salts |
| IL161491A0 (en) | 2001-11-07 | 2004-09-27 | Synthon Bv | Tamsulosin tablets |
| WO2004087123A1 (en) | 2003-04-01 | 2004-10-14 | Laboratoires Besins International | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| MXPA05006526A (es) | 2002-12-18 | 2006-02-17 | Besins Int Lab | Tratamiento de mastalgia con 4-hidroxi tamoxifen. |
| EP2050443B1 (en) | 2002-12-18 | 2017-05-24 | Besins Healthcare Luxembourg SARL | Reduction of breast density with 4-hydroxy tamoxifen |
| NZ544851A (en) | 2003-06-23 | 2008-03-28 | Macrochem Corp | A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant |
| US7531578B2 (en) | 2003-09-18 | 2009-05-12 | City Of Hope | Compounds and methods for treating breast cancer and other diseases |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| ATE548375T1 (de) | 2004-01-16 | 2012-03-15 | Cedarburg Pharmaceuticals Inc | Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung |
| US8436029B2 (en) | 2004-03-19 | 2013-05-07 | Transform Pharmaceuticals, Inc. | Pharmaceutical forms, and methods of making and using the same |
| US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| US20070059288A1 (en) | 2005-03-31 | 2007-03-15 | Dinsmore Jonathan H | Treatment for heart disease |
| US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
| JP2008516005A (ja) | 2005-07-06 | 2008-05-15 | シコール インコーポレイティド | レトロゾールの改良された調製方法 |
| US20080319092A1 (en) | 2005-08-05 | 2008-12-25 | Nuvo Research Inc. | Transdermal Drug Delivery Formulation |
| RU2008118363A (ru) | 2005-10-12 | 2009-11-20 | Кова Ко., Лтд. (Jp) | Ионтофоретический препарат для лечения рака молочной железы и/или мастита |
| US20090208944A1 (en) | 2005-12-09 | 2009-08-20 | Goetz Matthew P | Assessing outcomes for breast cancer patients treated with tamoxifen |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US9308181B2 (en) | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
| WO2007141799A1 (en) | 2006-06-05 | 2007-12-13 | Cadila Healthcare Limited | A process for preparing pure anastrozole |
| CA2665105A1 (en) | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and its' process of preparation |
| US20120164075A1 (en) * | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| IN2014MN00139A (enExample) | 2006-11-21 | 2015-06-19 | Jina Pharmaceuticals Inc | |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US20080207644A1 (en) | 2006-11-27 | 2008-08-28 | Sonis Stephen T | Therapeutic materials and methods |
| WO2008067991A2 (en) | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| CA2680825C (en) | 2007-03-22 | 2013-10-29 | Cytotech Labs, Llc | Topical formulations having enhanced bioavailability |
| WO2009032699A1 (en) | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
| AR068409A1 (es) | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
| EP2212301B1 (en) | 2007-11-28 | 2012-02-29 | Fresenius Kabi Oncology Limited | An improved process for preparation of letrozole and its intermediates |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| WO2009129352A2 (en) | 2008-04-15 | 2009-10-22 | Windy Hill Medical | Device and method for accessing and treating ducts of mammary glands |
| US8063249B1 (en) | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
| NZ590268A (en) | 2008-07-08 | 2012-11-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2010043404A1 (en) | 2008-10-15 | 2010-04-22 | Synthon B.V. | Processes and intermediates for the production of fulvestrant |
| US20100098659A1 (en) | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| ES2624557T3 (es) | 2008-12-11 | 2017-07-14 | Besins Healthcare Luxembourg Sarl | Composiciones farmacéuticas transdérmicas que comprenden un SERM |
| CN101891635B (zh) * | 2009-05-21 | 2014-06-04 | 扬子江药业集团有限公司 | 枸橼酸他莫昔芬的晶型及晶型a的制备方法 |
| US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| WO2011031561A2 (en) | 2009-08-27 | 2011-03-17 | Ensisheim Partners Llc | Nucleic acid molecules and uses thereof |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| WO2011072244A1 (en) | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
| EP2425833A1 (de) | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
| KR101308258B1 (ko) | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9200045B2 (en) | 2011-03-11 | 2015-12-01 | President And Fellows Of Harvard College | Small molecule-dependent inteins and uses thereof |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
| US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
| FR2980972B1 (fr) | 2011-10-05 | 2014-02-28 | Commissariat Energie Atomique | Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes. |
| US9353132B2 (en) | 2012-03-05 | 2016-05-31 | Xavier University Of Louisiana | Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer |
| US9220680B2 (en) | 2012-07-13 | 2015-12-29 | South Dakota State University | Compositions and methods for localized drug delivery through mammary papillae |
| US20150321983A1 (en) | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| PL2961831T3 (pl) | 2013-02-26 | 2020-12-14 | Memorial Sloan Kettering Cancer Center | Kompozycje i sposoby do immunoterapii |
| IN2013MU00646A (enExample) | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| TW201536278A (zh) * | 2013-05-31 | 2015-10-01 | Del Mar Pharmaceuticals | 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途 |
| CA2927752A1 (en) | 2013-10-18 | 2015-04-23 | The Regents Of The University Of Michigan | Systems and methods for determining a treatment course of action |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| WO2015106094A1 (en) | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
| CN106068121A (zh) | 2014-03-11 | 2016-11-02 | 利普生物药剂公司 | 使用单一溶剂进行克罗米芬合成 |
| JP6757935B2 (ja) | 2014-06-04 | 2020-09-23 | アトッサ ジェネティックス インク． | 分子マンモグラフィ |
| CN104230723B (zh) | 2014-08-21 | 2016-08-24 | 凯莱英医药集团（天津）股份有限公司 | 托瑞米芬的合成方法 |
| JP2018514511A (ja) | 2015-04-14 | 2018-06-07 | アトッサ ジェネティックス インク． | 乳房障害とエストロゲン関連障害の処置のための組成物と方法 |
| US10314854B2 (en) | 2015-05-15 | 2019-06-11 | University Of Iowa Foundation | Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy |
| JP2018520182A (ja) | 2015-07-14 | 2018-07-26 | アトッサ ジェネティックス インク． | 乳房障害を処置するための経乳頭方法及び組成物 |
| EP3365322B1 (en) * | 2015-10-22 | 2021-05-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Process for preparing (z)-endoxifen of high purity |
| DE102015222031A1 (de) * | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| US20170304232A1 (en) | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
| MX2020002683A (es) | 2017-09-11 | 2020-09-25 | Atossa Therapeutics Inc | Composiciones topicas y metodos de tratamiento. |
| KR20200051690A (ko) | 2017-09-11 | 2020-05-13 | 아토사 테라퓨틱스, 인크. | 국소 조성물 |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
-
2018
- 2018-09-10 EP EP18853361.6A patent/EP3681491A4/en active Pending
- 2018-09-10 JP JP2020511956A patent/JP7766316B2/ja active Active
- 2018-09-10 IL IL272924A patent/IL272924B2/en unknown
- 2018-09-10 IL IL319158A patent/IL319158A/en unknown
- 2018-09-10 AU AU2018329202A patent/AU2018329202B2/en active Active
- 2018-09-10 CN CN201880072905.6A patent/CN111328280A/zh active Pending
- 2018-09-10 US US16/641,985 patent/US11261151B2/en active Active
- 2018-09-10 IL IL304863A patent/IL304863B2/en unknown
- 2018-09-10 WO PCT/US2018/050272 patent/WO2019051416A1/en not_active Ceased
- 2018-09-10 CN CN202310795504.6A patent/CN116832020A/zh active Pending
- 2018-09-10 SG SG11202002105WA patent/SG11202002105WA/en unknown
- 2018-09-10 KR KR1020207010196A patent/KR20200052349A/ko not_active Ceased
- 2018-09-10 CA CA3073836A patent/CA3073836A1/en active Pending
- 2018-09-10 MX MX2020002649A patent/MX2020002649A/es unknown
- 2018-09-10 TW TW107131790A patent/TWI793165B/zh active
- 2018-09-10 KR KR1020247034641A patent/KR20240155974A/ko not_active Ceased
- 2018-09-10 TW TW112107353A patent/TWI878810B/zh active
-
2022
- 2022-01-20 US US17/580,428 patent/US11572334B2/en active Active
- 2022-12-29 US US18/090,757 patent/US11680036B1/en active Active
-
2023
- 2023-01-03 AU AU2023200013A patent/AU2023200013B2/en active Active
- 2023-03-30 US US18/128,536 patent/US12071391B2/en active Active
- 2023-07-18 JP JP2023116961A patent/JP2023126540A/ja active Pending
- 2023-10-31 US US18/499,120 patent/US12281056B2/en active Active
-
2024
- 2024-05-07 US US18/657,665 patent/US12275684B2/en active Active
- 2024-12-10 AU AU2024278243A patent/AU2024278243A1/en active Pending
-
2025
- 2025-01-27 JP JP2025011662A patent/JP2025061858A/ja active Pending
- 2025-01-30 US US19/041,975 patent/US20250282710A1/en active Pending
- 2025-03-28 US US19/094,756 patent/US12479790B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002649A (es) | Metodos para hacer y usar endoxifeno. | |
| CL2021000630A1 (es) | Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585) | |
| MX2022016566A (es) | Composiciones que comprenden una caseina y metodos para producir las mismas. | |
| CL2017002401A1 (es) | Anticuerpos contra icos | |
| DOP2017000150A (es) | Anticuerpos anti-cd 38 para el tratamiento de leucemia mieloides aguda | |
| PH12016501763B1 (en) | Multispecific antibodies | |
| WO2016001754A3 (en) | Methods for three dimensional reconstruction and determining the quality of an embryo | |
| MX2020004785A (es) | Proceso para preparar tapinarof. | |
| DOP2018000057A (es) | Composiciones biofarmacéuticas | |
| BR112018003800A2 (pt) | derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização | |
| BR112017001391A2 (pt) | componentes para o fusionamento de corpos vertebrais | |
| PE20180171A1 (es) | Neutralizacion del virus chikungunya mediada por anticuerpos | |
| MX2016014145A (es) | Composiciones de proteina con tamaño de particula pequeño y metodos para elaborarlas. | |
| MX374517B (es) | Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos. | |
| CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
| BR112016025024A2 (pt) | ?processo para preparar compostos ceto, e, uso de farnesil acetona? | |
| UY36602A (es) | Variantes de protoxina-ii y métodos de uso | |
| CO2018007237A2 (es) | Reguladores del cftr y métodos para su uso | |
| MX2017015279A (es) | Exasomas y su uso como vacunas. | |
| MX2018007415A (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida. | |
| UY36952A (es) | N-acetil-l-metionina bioderivada y uso de la misma | |
| CL2018001716A1 (es) | Reguladores del cftr y métodos para su uso | |
| BR112018073220A2 (pt) | processo para preparar artigos conformados para administração a animais | |
| MX2016015623A (es) | Proceso para la preparacion de derivados dihidroisoxazol. | |
| BR112016026684A2 (pt) | Fertilizante à base de enxofre |